DRI Capital closed its Drug Royalty II at $701 million last week, almost triple the $240 million raised in its 2006 fund, Drug Royalty I.

The firm's strategy will remain the same: purchasing royalties on approved biopharmaceutical products with demonstrated sales histories, according to Alex Leykikh of Atlantic-Pacific Capital. Atlantic-Pacific was the